B. Mennecier

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
B Mennecier, B. Mennecier, Bertrand Mennecier
Publication record
88 papers · 3,665 citations · H-index 20

PAPERS

40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
20231 citationsauthor #4
18FDG PET/CT Tumoral and Neurologic Therapeutic Response in a Case of Anti-GABABR Paraneoplastic Limbic Encephalitis.
20231 citationsauthor #3
Immunotherapy and Interventional Radiology: Two Optimal Allies in the Management of Bronchial Cancer
20220 citationsauthor #1
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
202225 citationsauthor #4
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.
20228 citationsauthor #8
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
20228 citationsauthor #5
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network.
202111 citationsauthor #8
Re: Two centres' experience with lung cancer resection in patients with advanced non-small-cell lung cancer following treatment with immune checkpoint inhibitors: safety and clinical outcomes.
20210 citationsauthor #1
1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib
20213 citationsauthor #5
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.
20204 citationsauthor #4
1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
20201 citationsauthor #4
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
2020117 citationsauthor #8
Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network.
20206 citationsauthor #9
Sarcoidosis reactivation with immune checkpoint inhibitors
20201 citationsauthor #3
1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
20202 citationsauthor #5
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial
202017 citationsauthor #12
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
2019174 citationsauthor #13
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
201922 citationsauthor #15
Brigatinib in pretreated patients with ALK-positive advanced NSCLC.
20195 citationsauthor #5
Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.
201913 citationsauthor #4
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
201927 citationsauthor #5
Lung resection and immunotherapy: two allied for a new hope in lung cancer cure.
20180 citationsauthor #1
OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
201814 citationsauthor #10
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients
201815 citationsauthor #11
[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
201815 citationsauthor #5
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
20185 citationsauthor #11
KRAS‐specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small‐cell Lung Cancer
201815 citationsauthor #7
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
201874 citationsauthor #8
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
20187 citationsauthor #4
P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial
20180 citationsauthor #11
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
2017149 citationsauthor #5
Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.
201617 citationsauthor #4
IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC
20160 citationsauthor #11
Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.
201620 citationsauthor #7
[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
20160 citationsauthor #2
Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy
20165 citationsauthor #3
Supplementary Material for: Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy
20160 citationsauthor #3
Successful treatment with ceritinib after crizotinib induced hepatitis.
201615 citationsauthor #2
IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC.
20150 citationsauthor #10
Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification
201521 citationsauthor #9
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
20151,383 citationsauthor #10
3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience
20150 citationsauthor #4
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
201511 citationsauthor #4
Late-Breaking Abstracts e 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
20142 citationsauthor #13
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units
201436 citationsauthor #7
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.
201442 citationsauthor #3
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
201414 citationsauthor #10
Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
201412 citationsauthor #3
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients
201424 citationsauthor #4
[Afatinib (BIBW 2992)].
20143 citationsauthor #3
CT lung cancer screening: where are we heading to?
20140 citationsauthor #2
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
20139 citationsauthor #18
[Hemolytic anemia under erlotinib treatment].
20131 citationsauthor #2
Impact of 3 D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer : A Prospective Study
20132 citationsauthor #8
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
2012105 citationsauthor #5
Impact of 3D Conformal Radiotherapy on Lung Function of Patients with Lung Cancer: A Prospective Study
201215 citationsauthor #8
[Muscular metastasis from primary lung cancer: about seven cases].
20112 citationsauthor #2
[Clinical case No. 1 proposed by the E Quoix (CHRU Strasbourg) team].
20100 citationsauthor #1
[Thyroid metastasis of lung cancer and abnormal thyroid function--a case report].
20092 citationsauthor #5
A two-faced young woman.
20093 citationsauthor #3
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort
2008198 citationsauthor #8
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
2008268 citationsauthor #6
Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy
20086 citationsauthor #4
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
200847 citationsauthor #6
[The actual place of anti-angiogenesis in non-small cell lung cancer].
20070 citationsauthor #1
[Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report].
20073 citationsauthor #6
ERS School Course Early-stage lung cancer - What's new in the epidemiology of lung cancer: the female aspect
20066 citationsauthor #2
[Pituitary metastases from lung cancer. Five cases].
20067 citationsauthor #2
[Lung cancer in elderly patients].
20050 citationsauthor #2
68 Efficacy of epoetin beta 30,000 IU once weekly in anaemic patientswith solid and non-myeloid haematological malignancies receiving chemotherapy
20050 citationsauthor #2
First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.
200521 citationsauthor #4
Chemoradiotherapy-induced esophagitis pain relieved by topical morphine: three cases.
20056 citationsauthor #3
P-963 A phase II study evaluating the clinical efficacy of TG4010(MVA-MUC1-IL2) in association with cisplatin and vinorelbine in patients with non small cell lung cancer
20052 citationsauthor #1
[Duplication of the superior vena cava and other malformations discovered at insertion of a port-a-cath].
20052 citationsauthor #3
[Treatment of small cell lung cancer (2003 update)].
20040 citationsauthor #1
[Coagulation disorders and arterial thromboembolic events in non-small-cell lung cancer. A case report].
20043 citationsauthor #2
MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data
20043 citationsauthor #3
MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data.
20046 citationsauthor #3
Salvage Therapy in Non-Small Cell Lung Cancer
20040 citationsauthor #2
[Lung cancer and pollution].
20033 citationsauthor #2
Women and small cell lung cancer: social characteristics, medical history, management and survival: a retrospective study of all the male and female cases diagnosed in Bas-Rhin (Eastern France) between 1981 and 1994.
200331 citationsauthor #1
Multitargeted antifolate (Pemetrexed): A comprehensive review of its mechanisms of action, recent results and future prospects
20036 citationsauthor #3
Concurrent cisplatin/etoposide chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung cancer: a phase II study.
200015 citationsauthor #1
[Acute pleuro-pneumonitis resulting from leptospirosis].
20000 citationsauthor #1
True progress in survival of patients (pts) with small cell lung cancer (SCLC) over a period of 14 years
20001 citationsauthor #7
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
1999546 citationsauthor #4
[Paraneoplastic Cushing's syndrome and small cell bronchial carcinoma].
19997 citationsauthor #1
[Late manifestation of common variable immunodeficiency by Biermer's disease].
19980 citationsauthor #2

TIMELINE

1998 0 citations

1999 553 citations

2000 16 citations

2003 40 citations

2004 12 citations

2005 31 citations

2006 13 citations

2007 3 citations

2008 519 citations

2009 5 citations

2010 0 citations

2011 2 citations

2012 120 citations

2013 12 citations

2014 133 citations

2015 1,415 citations

2016 57 citations

2017 149 citations

2018 145 citations

2019 241 citations

2020 148 citations

2021 14 citations

2022 41 citations

2023 2 citations

B. Mennecier

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT